ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Carcinoma, Transitional Cell
Astellas Pharma Global Development, Inc.antibody_drug_conjugatePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Carcinoma, Transitional Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MITOMYCIN C UroGen Pharma Ltd. | Phase 3 | B |
Vinflunine Bristol-Myers Squibb | Phase 2 | B |
Brivanib Bristol-Myers Squibb | Phase 2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Astellas Pharma Global Development, Inc. | Phase 1/2 | B |
Carboplatin Astellas Pharma Global Development, Inc. | Phase 1/2 | B |
View all 20 →
Same molecule, other indications
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →